ストックスクリーナーアプリを入手
7.35
0.27%
0.02
プレマーケット:
7.40
0.05
+0.68%
Gyre Therapeutics Inc (GYRE) 最新ニュース
Gyre Therapeutics stock holds steady as investors await next clinical and earnings milestones - AD HOC NEWS
Gyre Therapeutics, Inc.Common Stock (Nasdaq:GYRE) Detailed Stock Data - The Chronicle-Journal
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a 159.98% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Gyre Therapeutics Q2 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Rise 6.57%Earnings Growth Forecast - careplusvn.com
GYRE: Integrated China-U.S. model drives innovation, revenue, and a robust clinical pipeline - TradingView
GYRE: Integrated China-U.S. model drives pipeline growth, with key catalysts in fibrosis and cancer pain - TradingView
GYRE Q2 2026 Earnings: Wider-than-Expected Loss But Shares Advance 4.52%Full Year Guidance - careplusvn.com
Gyre Therapeutics to Participate in Upcoming September Investor Conferences - The Manila Times
Two live online healthcare talks will feature Gyre Therapeutics this month - Stock Titan
Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy - The Globe and Mail
Gyre updates corporate presentation, outlines China-driven R&D and F351 regulatory progress - TradingView
Gyre Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
GYRE Q2 2026 Earnings: Wider Net Loss of $0.12 Per Share Highlights Clinical-Stage SpendingMargin Compression Risk - dars.gov.et
Gyre Therapeutics unveils capital-efficient global development strategy - The Globe and Mail
Gyre Therapeutics posts updated corporate presentation detailing pipeline progress and China-commercial revenue drivers - TradingView
Gyre (GYRE) Results Review: The EPS Result Is Below Expectation in the Latest Session; After Results: Shares Move 1.82% Down for the Current SessionBalance Sheet Strength - vinanet.vn
Gyre (GYRE): Slides 2.10% to $7.00 in Latest Trading; Trading Range: Price Remains Between $6.65 Support and $7.35 ResistanceBackspread Trade - vinanet.vn
Gyre Therapeutics (NASDAQ:GYRE) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat
Analysts Set Expectations for GYRE Q3 Earnings - MarketBeat
GYRE | Gyre Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Claire Weston Net Worth (2026) - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN) - The Globe and Mail
Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Gyre Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Gyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gyre Therapeutics earnings missed by $0.06, revenue topped estimates - Investing.com Nigeria
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Lights a Fire Under SharesEarnings Deceleration Risk - careplusvn.com
Gyre Therapeutics (NASDAQ:GYRE) Issues Earnings Results - MarketBeat
Form 8K Gyre Therapeutics Inc For: 7 August By Investing.com - Investing.com Nigeria
GYRE: Net loss widened to $32.8 million on $53.5 million revenue, with strong liquidity maintained - TradingView
Gyre Therapeutics (NASDAQ: GYRE) swings to 32,849 H1 2026 net loss - Stock Titan
Gyre Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
H.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Gyre Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gyre Therapeutics Q2 EPS misses estimate despite sales beat - scanx.trade
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Gyre Therapeutics Sees 2026 Rev $100.5M-$111.0M >GYRE - Moomoo
Gyre Therapeutics Reports Second Quarter 2026 - Moomoo
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
GYRE Q2 Revenue Falls To $29.1 Million As Net Loss Widens - Quiver Quantitative
GYRE: Q2 2026 revenue reached $29.1M, net loss widened, and Cullgen acquisition expanded the pipeline - TradingView
Gyre Therapeutics reports Q2 2026 revenue $29.1M, GAAP EPS $(0.12); full-year revenue guidance affirmed - TradingView
Gyre Therapeutics, Inc. Affirms Earnings Guidance for the Full Year of 2026 - marketscreener.com
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: A 191% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
About $300M Cullgen deal adds cancer candidates to Gyre's pipeline - Stock Titan
L9S.DU interactive stock chart | Gyre Therapeutics Inc. R stock - Yahoo Finance Australia
Gyre Therapeutics, Inc. (GYRE) grants director options on 40,000 shares - Stock Titan
Gyre Therapeutics (GYRE) director discloses no stock ownership - Stock Titan
Gyre Therapeutics (GYRE) awards director 40,000 stock options vesting to 2029 - Stock Titan
Weston Claire files initial ownership report at Gyre Therapeutics (GYRE) - Stock Titan
Gyre Therapeutics director Kirkby Maxwell files initial beneficial ownership statement - Bitget
GYRE THERAPEUTICS, INC. SEC Filing (Aug 4, 2026) - Stock Titan
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Gyr - The National Law Review
Gyre Therapeutics (GYRE) to Post Quarterly Earnings on Monday - MarketBeat
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 39.84% as Shares Slip 1.03%Profitability Analysis - careplusvn.com
Gyre Therapeutics, Inc. (GYRE) Investor Outlook: Exploring a Promising 221% Upside in Biotech - DirectorsTalk Interviews
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 5.8%Here's Why - MarketBeat
Gyre Therapeutics Inc (GYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gyre Therapeutics Inc (GYRE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gyre Therapeutics Inc (GYRE) Balance Sheet - TradingKey
Gyre Therapeutics Inc (GYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gyre Therapeutics Inc (GYRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gyre Therapeutics Inc (GYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GYRE|Gyre Therapeutics Inc|Price:6.110|Chg%:+0.170 - TradingKey
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):